Highlights from Heart Rhythm Society 2017: Innovations in Electrophysiology Patient Management, and Beyond

Abstract

On the other hand, it is possible that AF detected by ICM does increase stroke in the long term. The risk might become apparent as the PREDATE AF, ASSERT II, and REVEAL AF cohorts are followed long term. Can anticoagulation for ICM-detected silent AF reduce stroke risk significantly? The ongoing NOAH (https:// clinicaltrials.gov/ct2/show/NCT02618577) and ARTESiA (https://clinicaltrials.gov/ct2/show/NCT01938248) trials are expected to provide much-needed information regarding the modification of stroke risk in patients with incidentally detected AF.